Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation TCT 2025

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

Presenter: Hisao Otsuki

October 26, 2025

Presentation TCT 2025

Recent Coronary Trials: Role of Physiology - Put the Brakes On! (FAME 3; FAVOR 3; FLOWER MI)

Presenter: Kyung Woo Park

October 26, 2025

Presentation TCT 2025

Cost-Effectiveness of CABG vs. PCI for Multivessel Disease: The FAME 3 Trial

Presenter: Mark Andrew Hlatky

October 25, 2025

Presentation TCT 2024

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

Presenter: Kuniaki Takahashi

October 28, 2024

Presentation TCT 2023

TCT 340: Sex Differences in Patients with Three-vessel Coronary Artery Disease Undergoing FFR-guided PCI or CABG: A Pre-specified Analysis of the FAME 3 Trial

Presenter: Kuniaki Takahashi

October 26, 2023

Presentation TCT 2023

TCT 142: Impact of Chronic Total Occlusions on Outcomes in The FAME 3 Trial

Presenter: Hisao Otsuki

October 24, 2023

Presentation TCT 2021

FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG

Presenter: William Fearon

November 04, 2021

Presentation TCT 2019

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

Presenter: William Fearon

September 27, 2019

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

Presentation TCT 2017

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, William F. Fearon

November 02, 2017

Presentation TCT 2017

How to Interpret Trials That Are Stopped Early (eg, PRAMI, FAME II, DECISION CTO, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Laura Mauri

October 30, 2017

Presentation TCT 2014

From FAME 1 to FAME 3: The Functional SYNTAX Score

Presenter: Bernard De Bruyne, Manesh R. Patel, Allen Jeremias, William F. Fearon

September 14, 2014

Presentation TCT 2013

TCT-76. Does Age Affect Fractional Flow Reserve-Guided Percutaneous Coronary Intervention? A FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Trial...

Presenter: Hong-Seok Lim

October 29, 2013

Presentation TCT 2012

FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease

Presenter: William Fearon

October 24, 2012

Advertisement

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

Recent Coronary Trials: Role of Physiology - Put the Brakes On! (FAME 3; FAVOR 3; FLOWER MI)

Cost-Effectiveness of CABG vs. PCI for Multivessel Disease: The FAME 3 Trial

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

TCT 340: Sex Differences in Patients with Three-vessel Coronary Artery Disease Undergoing FFR-guided PCI or CABG: A Pre-specified Analysis of the FAME 3 Trial

TCT 142: Impact of Chronic Total Occlusions on Outcomes in The FAME 3 Trial

FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

How to Interpret Trials That Are Stopped Early (eg, PRAMI, FAME II, DECISION CTO, and Others)

From FAME 1 to FAME 3: The Functional SYNTAX Score

TCT-76. Does Age Affect Fractional Flow Reserve-Guided Percutaneous Coronary Intervention? A FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Trial...

FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content